Chikungunya vaccines - only as and when needed....

insect on the bulls eye of a target

This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Chikungunya vaccines. Relative to other healthcare priorities in affected countries, is a Chikungunya vaccine high on the list?

Chikungunya virus (CHIKV) is an arthropod-borne RNA virus (arbovirus) of the Togaviridae family which can cause acute illness in humans. Patients usually present with high fever, severe incapacitating arthralgia (joint pain) and skin rash. In some cases, the virus can also cause a chronic disease (> 3 months) which resembles rheumatoid arthritis (post-CHIKV rheumatic disorder). Other atypical findings such as neurological complications, cardiovascular and respiratory symptoms are described. The impact of CHIKV in children can also have severe consequences.

CHIKV infection is generally not considered a life-threatening disease, with an estimated case-fatality rate (CFR) of 0.1%. However, the main concern is CHIKV’s large-scale health impact. CHIKV epidemics can be explosive where case numbers reach hundreds of thousands. Importantly, large proportions of immunological naïve populations are affected by debilitating symptoms. CHIKV can place a significant burden on already strained healthcare infrastructures in developing countries. Furthermore, the establishment of mosquito vectors (due to climate change) has increased the number of countries reporting CHIKV cases from 60 in 2014 to ~116 as of September 2019 (US CDC figures). Italy, Spain, France and USA have reported local CHIKV cases.

A number of potential CHIKV vaccine candidates (based on various approaches) are now in the clinical stages of development including those from Emergent BioSolutionsThemis Bio GmbH and Valneva Austria GmbH. These candidates have received US and EU fast track regulatory designations underscoring their high medical need, and recently, the Coalition of Epidemic Preparedness Innovations (CEPI) has also disbursed funds to ongoing efforts. Now, regulators are considering new accelerated pathways to licensure based on immunogenicity (ICOP) rather than conducting a Phase III efficacy study. Once proven to be safe, a CHIKV vaccine could be available from 2022/23 onwards and used in vulnerable populations in both endemic public/private markets and possibly in Western travelers (profile dependent). 

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>200 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic Chikungunya vaccine to 2035. The prospects of the vaccine in First time and Repeat Western travelers (Visiting Friends/Family and Business + Other), endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined. A newly engineered model for 2020 now explores a mixed vaccine schedule (1 dose/2 dose) market whereby competitor entrance scenarios can be visualized. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided.

VacZine Analytics is an established strategic research agency based in the United Kingdom. We aim to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.For more information, please visit the website or contact info@vaczine-analytics.comVacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company No. 5807728

Copyright. All Rights Reserved, 2020



VacZine Analytics is an established strategic research publisher based in the United Kingdom.

VacZine Analytics Ltd (Assay Advantage)